세계의 현기증 치료제 시장 2019-2023

■ 영문 제목 : Global Vertigo Drugs Market 2019-2023

Technavio가 발행한 조사보고서이며, 코드는 IRTNTR30478 입니다.■ 상품코드 : IRTNTR30478
■ 조사/발행회사 : Technavio
■ 발행일 : 2018년 12월 11일
■ 페이지수 : 122
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일
■ 조사대상 지역 : 글로벌, 미주, 유럽, 아시아
■ 산업 분야 : 의료
■ 판매가격 / 옵션 (부가세별도)
Single User (1명 열람용)USD2,500 ⇒환산₩2,750,000견적의뢰/주문/질문
Five User (5명 열람용)USD3,000 ⇒환산₩3,300,000견적의뢰/주문/질문
Enterprise License (전사내 공유가능)USD4,000 ⇒환산₩4,400,000견적의뢰/구입/질문
가격옵션 설명
- 지불하실 금액은 상기 원화금액에 부가세(10%)를 더한 금액입니다.
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제이며, 세금계산서 발행 가능합니다.
본 조사보고서는 현기증 치료제의 세계시장에 대해서 조사분석한 자료로서, 현기증 치료제의 세계시장규모, 시장동향, 시장환경 분석, 세그멘트별 분석, 지역별 분석 (미주, 유럽, 아시아), 관련기업 정보등이 포함되어 있습니다.
■ 보고서 개요

About this marketVertigo mostly occurs due to inner ear infections or other conditions such as benign paroxysmal positional vertigo (BPPV), vestibular neuritis, and Meniere’s disease. These conditions are high-risk factors for vertigo. The prevalence of these risk factors is high globally. Another significant cause for vertigo is vestibular neuritis that is an infection in the inner ears. The infection causes inflammation around the nerves that help the body sense balance. As a result, this infection causes a severe sensation of vertigo that can last for a couple of days and at times coupled with hearing loss. Vestibular neuritis or BPPV may have a low prevalence rate individually. However, when combined, these risk factors of vertigo have a high prevalence rate. As a result, the growth of the global vertigo drugs market would be significant during the forecast period. Technavio’s analysts have predicted that the vertigo drugs market will register a CAGR of close to 4% by 2023.
Market Overview
Increasing geriatric population
The prevalence of dizziness increases with age. Therefore. rising the geriatric population becomes the driving factor for the growth of the global vertigo drugs market. The aging world population is contributing to the rapid increase in the number of people with vertigo. Therefore, the increasing geriatric population will be driving the growth of the global vertigo drugs market during the forecast period.
Adversely effects of the available therapeutics
The market has the presence of a few approved therapeutics for the treatment of various risk factors of vertigo. These drugs are classified into phenothiazines. antihistamines. benzodiazepines. and others. However. most of these therapeutics cause adverse effects when consumed for a long duration.
For the detailed list of factors that will drive and challenge the growth of the vertigo drugs market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be highly fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

■ 보고서 목차

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Antihistamines – Market size and forecast 2018-2023
• Phenothiazines – Market size and forecast 2018-2023
• Benzodiazepines – Market size and forecast 2018-2023
• Other drugs – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
• Increasing awareness of vertigo and related diseases
• Strategic alliances for ear diseases
• Growing e-commerce market
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Novartis
• Pfizer
• Teva Pharmaceutical Industries
PART 13: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global ENT disorders therapeutics market
Exhibit 03: Segments of global ENT disorders therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antihistamines – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antihistamines – Year-over-year growth 2019-2023 (%)
Exhibit 22: Phenothiazines – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Phenothiazines – Year-over-year growth 2019-2023 (%)
Exhibit 24: Benzodiazepines – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Benzodiazepines – Year-over-year growth 2019-2023 (%)
Exhibit 26: Other drugs – Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Other drugs – Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Increasing prevalence of dizziness with the age
Exhibit 34: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Americas
Exhibit 36: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in EMEA
Exhibit 40: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 41: Geriatric population in APAC
Exhibit 42: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in APAC
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Decision framework
Exhibit 47: Global geriatric population
Exhibit 48: Adverse effects of the drugs
Exhibit 49: Impact of drivers and challenges
Exhibit 50: Awareness initiatives of vertigo
Exhibit 51: Vendor landscape
Exhibit 52: Landscape disruption
Exhibit 53: Vendors covered
Exhibit 54: Vendor classification
Exhibit 55: Market positioning of vendors
Exhibit 56: F. Hoffmann-La Roche – Vendor overview
Exhibit 57: F. Hoffmann-La Roche – Business segments
Exhibit 58: F. Hoffmann-La Roche – Organizational developments
Exhibit 59: F. Hoffmann-La Roche – Geographic focus
Exhibit 60: F. Hoffmann-La Roche – Segment focus
Exhibit 61: F. Hoffmann-La Roche – Key offerings
Exhibit 62: F. Hoffmann-La Roche – Key customers
Exhibit 63: GlaxoSmithKline – Vendor overview
Exhibit 64: GlaxoSmithKline – Business segments
Exhibit 65: GlaxoSmithKline – Organizational developments
Exhibit 66: GlaxoSmithKline – Geographic focus
Exhibit 67: GlaxoSmithKline – Segment focus
Exhibit 68: GlaxoSmithKline – Key offerings
Exhibit 69: GlaxoSmithKline – Key customers
Exhibit 70: Novartis – Vendor overview
Exhibit 71: Novartis – Business segments
Exhibit 72: Novartis – Organizational developments
Exhibit 73: Novartis – Geographic focus
Exhibit 74: Novartis – Segment focus
Exhibit 75: Novartis – Key offerings
Exhibit 76: Novartis – Key customers
Exhibit 77: Pfizer – Vendor overview
Exhibit 78: Pfizer – Business segments
Exhibit 79: Pfizer – Organizational developments
Exhibit 80: Pfizer – Geographic focus
Exhibit 81: Pfizer – Segment focus
Exhibit 82: Pfizer – Key offerings
Exhibit 83: Pfizer – Key customers
Exhibit 84: Teva Pharmaceutical Industries – Vendor overview
Exhibit 85: Teva Pharmaceutical Industries – Business segments
Exhibit 86: Teva Pharmaceutical Industries – Organizational developments
Exhibit 87: Teva Pharmaceutical Industries – Geographic focus
Exhibit 88: Teva Pharmaceutical Industries – Segment focus
Exhibit 89: Teva Pharmaceutical Industries – Key offerings
Exhibit 90: Teva Pharmaceutical Industries – Key customers
Exhibit 91: Validation techniques employed for market sizing
Exhibit 92: List of abbreviations



■ 기재된 기업 리스트

F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Pfizer, and Teva Pharmaceutical Industries


■ 조사 방법

1차조사 (업계 전문가, 기업, 대리점, 고객에 대한 심층 인터뷰를 포함), 2차조사 (Technavio 플랫폼, 산업자료, 기업 보고서, 뉴스 기사, 애널리스트 레포트, 무역협회, 정부발행 자료 등)

※본 조사보고서 [세계의 현기증 치료제 시장 2019-2023] (코드 : IRTNTR30478) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [세계의 현기증 치료제 시장 2019-2023] 에 대해서 E메일 문의는 여기를 클릭하세요.